Unfractionated Heparin Market New Trends, Market
Segmentation, Footprint With Their Financial
Condition By 2026
Unfractionated heparin (UFH) is a natural agent widely used to prevent clot formation in
vessels. Unfractionated heparin is a fast-acting blood thinner, which works with antithrombin, a
natural protein in the body, to block clot formation. UFH is administered to patient
intravenously into an arm vein or as a subcutaneous injection under the skin. UFH can also be
administrated orally. However, oral absorption of unfractionated heparin is poor, owing to their
size and anionic structure. UFH is not absorbed properly from the gastrointestinal tract when
taken orally.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1672
Unfractionated heparin is majorly used in deep venous thrombosis (DVT), pulmonary embolism
(PE), and venous thromboembolism (VTE) in patients with increased postoperative
complications. Unfractionated heparin is the preferred treatment for patients at high risk of
bleeding complications, owing to its short activity and reversibility and its reversible
anticoagulant effect. Additionally, UTH offers various advantages over other types of heparin,
owing to its ability to rapidly enter into the blood stream and less reliant to kidney for
extraction. UTH is a preferred anticoagulant option for pregnant women, as it does not cross
the placenta, and thus is considered as safe for the fetus.
Unfractionated Heparin Market Drivers
Growth of unfractionated heparin market is increasing, owing to the increasing incidence of
thromboembolic disorders such as deep vein thrombosis and pulmonary embolism, and among
others. According to the data findings published in the Centers for Disease Control and
Prevention (CDC), in February 2018, 900,000 people are affected (1 to 2 per 1,000) each year
in the U.S. due to the deep venous thromboembolism and Pulmonary Embolism (DVT/PE).
According to data published in the Circulation Research Journal: a journal of the American
Heart Association, in 2016, the incidence of venous thromboembolism (VTE) increases with